CP and chronic myelogenous leukemia, BCR-ABL1 positive: This implies improved efficacy of the combination treatment at this phase of the disease, especially when the concentration of IM in combination therapy is lower than that normally used, at a range of 1–5 μM, in in vitro studies (at 400 mg/day, the current standard dose for CML-CP, peak levels at steady state is ~5 μM) [44].